Project Grant R43AI172560
Award Date 5/5/23
Completion Date 10/31/24
Dollars Obligated $250K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Similar Awards
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,013,468 to Inhalon Biopharma, Inc. to advance the development of IN-003PI, a passive immunization treatment against human metapneumovirus (MPV) infections. The funding will support key research activities such as producing GLP-compliant antibody batches, conducting IND-enabling toxicology and efficacy studies, and...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $433,175 to develop a mosaic mRNA vaccine to prevent hand, foot and mouth disease (HFMD). The goal is to create a broadly protective vaccine that can address the diverse viral strains that cause HFMD, which is primarily caused by human enterovirus serotype A viruses and can lead to severe complications like viral...
- The federal Project Grant award of $734,184.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to elucidate the mechanism of genome replication for non-segmented negative-strand RNA viruses, including paramyxoviruses such as human parainfluenza virus type 3 (HPIV-3). The grant, awarded to Trustees of Boston University Medical Campus, aims to characterize the structure and...
- The University of Missouri System, under a $650,000 project grant from the USDA National Institute of Food and Agriculture (NIFA) Agriculture and Food Research Initiative (AFRI) program, is developing safe and effective live attenuated swine influenza vaccines using Newcastle disease virus (NDV) as the vector. The project aims to address the challenges with current swine influenza vaccines, which often fail to provide cross-protection against diverse virus strains. The key products and...
- This Project Grant award of $458,250.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a VP4-based pseudovirus nanoparticle rotavirus vaccine for oral immunization. The award will fund research to create a non-replicating rotavirus vaccine candidate called S-VP4E, which consists of a calicivirus inner shell and multiple rotavirus spikes (VP4E) on the surface. This...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $308,669 Project Grant under the Allergy and Infectious Diseases Research Program (CFDA 93.855) to Vishenary, LLC to develop a novel vaccine with broad efficacy against nontypeable Haemophilus influenzae (NTHI) strains following influenza A virus (IAV) infection. The project aims to create a vaccine candidate consisting of a conserved NTHI protein (Protein 0259) and the FDA-approved histone deacetylase inhibitor...
- The federal Cooperative Agreement award U19AI181984, totaling $44,108,652.00, was granted by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The purpose of this 3-year award is to develop vaccines and antibody-based treatments for viruses in the Paramyxoviridae, Peribunyaviridae, and Phleboviridae families, with a focus on prototype viruses such as human parainfluenza virus 3 (HPIV3), Oropouche virus...
- This $649,896 federal Project Grant awarded by the U.S. Department of Agriculture's (USDA) National Institute of Food and Agriculture (NIFA) under the Agriculture and Food Research Initiative (AFRI) program supports the development and testing of an mRNA vaccine cocktail against influenza A viruses (IAV) in livestock. The project aims to create a universal influenza vaccine that can provide broad protection against diverse IAV strains, including highly pathogenic avian influenza (HPAI) H5N1...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop novel multivalent mucosal vaccines for human noroviruses. The total funding is $798,173 with a project period from May 1, 2025 to April 30, 2030. The key products and services to be delivered include: 1) Developing multivalent, live-vectored mucosal norovirus vaccines using FDA-approved rotavirus (RotaTeq)...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,968 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Viva Viral Vaccines, Inc. to develop a broad-spectrum, multivalent vaccine platform for pandemic and seasonal influenza. The platform leverages innovations in the production of influenza neuraminidase (NA) proteins in mammalian cells, enabling the development of VLP-based vaccines that can provide broad heterologous...